Application of immunosuppressive agents in pregnancy after organ transplantation

doi:10.12092/j.issn.1009-2501.2018.11.020

Abstract

Abstract:

Immunosuppressive agents are widely used in patients after organ transplantation, including calcineurin inhibitors, azathioprine, mycophenolate mofetil, glucocorticoids, etc. However, the safety of immunosuppressive agents in pregnancies is not well defined, which limits the use of these drugs. Therefore, safe and effective immunosuppressant during pregnancy has received much attention. This article will review the current commonly used immunosuppressive agents during pregnancy after organ transplantation.

Key words: immunosuppressive, pregnancy, organ transplantation

CLC Number:

YAN Lin, WANG Jingjing, HUANG Hua, YAO Qin, LI Qian, ZHANG Jun. Application of immunosuppressive agents in pregnancy after organ transplantation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1317-1320.

References

［1］Blume C, Pischke S, von Versen-Hoynck F, et al. Pregnancies in liver and kidney transplant recipients: a review of the current literature and recommendation ［J］. Best Pract Res Clin Obstet Gynaecol, 2014, 28(8): 1123-1136.
［2］孙晓东, 叶军锋, 付裕, 等. 美国肝病学会和美国移植学会2012年实践指南: 成人肝移植成功后的长期管理［J］. 临床肝胆病杂志, 2013, 29(6): 1-15.
［3］张丹波, 倪晓洁, 杨亦荣, 等. 肾移植术后妊娠九例十次临床分析［J］. 中华移植杂志(电子版), 2017, 11(4): 206-210.
［4］Colombo D. Cyclosporine in transplantation-a history of converging timelines ［J］. J Biol Regul Homeost Agents, 2011, 25(4): 493-504.
［5］石炳毅, 袁铭. 中国肾移植受者免疫抑制治疗指南(2016版)［J］. 器官移植, 2016, 7(5): 327-331.
［6］许龙根. 女性肾移植受者的妊娠与生育问题［J］. 中华移植杂志(电子版), 2015, 9(1): 6-12.
［7］Kim J, Park J, Hwang S, et al. Ten-year observational follow-up of a randomized trial comparing cyclosporine and tacrolimus therapy combined with steroid withdrawal in living-donor renal transplantation［J］. Clin Transpl, 2018, 32(19): 133-145.
［8］Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus ［J］. Transplantation, 2000, 70(12): 1718-1721.
［9］吴玉仙, 周洋, 张夕, 等. 不同免疫抑制剂对肾移植术后孕妇发生妊娠期高血压的临床分析［J］. 生殖与避孕, 2016, 36(12): 992-997.
［10］Zheng S, Easterling TR, Hays K, et al. Tacrolimus placental transfer at delivery and neonatal exposure through breast milk ［J］. Brit J Clin Pharmacol, 2013, 76(6): 988-996.
［11］Perales-Puchalt A, Vila Vives JM, López Montes J, et al. Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison［J］. J Matern Fetal Neonatal Med, 2012, 25(8): 1363-1366.
［12］Gentile S. The safety of newer antidepressants in pregnancy and breastfeeding ［J］. Drug Saf, 2005, 28(2): 137-152.
［13］Armenti VT, Constantinescu S, Moritz MJ. Pregnancy after transplantation ［J］. Transplant Rev, 2008, 22(4): 223-240.
［14］Aktürk S, elebi ZK, Erdogmuss, et al. Pregnancy after kidney transplantation: outcomes, tacrolimus doses, and trough levels ［J］. Transplant Proc, 2015, 47(5): 1442-1444.
［15］Zaffar N, Soete E, Gandhi S, et al. Pregnancy outcomes following single and repeat liver transplantation: An international 2-center cohort ［J］. Liver Transpl, 2018, 24(6): 769-778.
［16］Shah S. Overview of pregnancy in renal transplant patients ［J］. Int J Nephrol, 2016, 2016(6): 453-460.
［17］Cleary BJ. Early pregnancy azathioprine use and pregnancy outcomes ［J］. Birth Defects Res A Clin Mol Teratol, 2009, 85(7): 647-654.
［18］Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine ［J］. Teratology, 2002, 65(5): 240-261.
［19］Coscia LA, Constantinescu S, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation［J］. Clin Transpl, 2010: 65-85.
［20］Garritsen FM, van den Broek MPH, van Zuilen AD, et al. Pregnancy and fetal outcomes after paternal exposure to azathioprine, methotrexate or mycophenolic acid: a critically appraised topic［J］. Brit J Dermatol, 2017, 176(4): 866-877.
［21］李丽莎, 尹佳. 妊娠期哮喘用药的安全性［J］. 中华临床免疫和变态反应杂志, 2017, 11(2): 184-191.
［22］Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies ［J］. Teratology, 2016, 62(6): 385-392.

[1]	LIU Xin, LENG Yufang, ZHANG Xuehong, ZHANG Lili, ZHANG Mengjie, QU Shanshan, XIE Jianqin, WANG Yiqing. Application of nalbuphine in ultrasound-guided transvaginal oocyte retrieval and its effect on embryo quality and pregnancy outcome [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1042-1047.
[2]	JIANG Weijie, HE Haibo, TANG Hongbo, HE Junyu. Research progress on the relationship between nuclear factor-κB in placenta and pregnancy complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 82-87.
[3]	WANG Sijie，ZHANG Jun，LI Qian，HUANG Hua，WANG Jingjing，ZHOU Qiong，YAO Qin. Research progress on the safety and effectiveness of escitalopram in the treatment of pregnant women with depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1070-1074.
[4]	LU Xiaohong，WANG Peiguang. Progress in the treatment of dermatomyositis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 836-840.
[5]	YING Jiawei，WU Liang，SHENG Shaoqin. Clinical study on the treatment of salvia ligustrazine injection on pregnant women with ICP in late pregnancy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 446-450.
[6]	JIN Congcong, WANG Peiyu, LIN Jia, ZHOU Wei, YANG Haiyan. A comparison of clinical applications of transdermal estradiol and estradiol valerate on endometrial receptivity in frozen-thawed embryo transfer cycles [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1162-1166.
[7]	DU Xiang-hui, JI Yong-lin, WANG Xiao-jia. The influence of the drug on the fetus of diagnosis and treatment of breast cancer during pregnancy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 206-213.
[8]	XIONG Qin-mei, HONG Kui. Survey on anticoagulant therapy in pregnant women with cardiovascular disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 223-227.
[9]	ZHANG Nan, HE Lian-zhi. Analysis of long-dated security and effectiveness for high-grade cervical intraepithelial neoplasia with loop electrosurgical excision procedure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(12): 1411-1415.
[10]	CHEN Jun-xia, WANG Yun-gen, SHAN Jiang-jing, RUAN Ya-wen. Efficacy comparison of two methotrexate regimen in the non-surgical treatment for ectopic pregnancy with different pre-treatment β-HCG rising ratio [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(11): 1270-1274.
[11]	DING Hua-feng, HE Lian-zhi, SHI Su-hua. Curative effect of MTX combined with mifepristone in the treatment of tubal pregnancy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 445-447.
[12]	WANG Yan, BU Wen-ting, LI Peng-fei, MA Ping, GAO Wen-jing, SUN Jian-zi. Advancement of the drug monitoring methods of immunodepressants in human blood [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 830-836.
[13]	YANG Hai-yan, ZHAO Jun-zhao, LIN Jin-ju, YU Rong. Effects of estradiol valerate supplementation on the pregnancy outcome in patients with endometrial thickness less than 7 mm on the day of embryo transfer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1277-1281.
[14]	FAN Jian-feng, TANG Sheng-xing, WAN Jun, ZHU Wei-ping, LI Bi-long, ZHU Zheng-cai. Variations of pregnancy-associated plasma protein-A and C-reactive protein in essential hypertension patients with left ventricular hypertrophy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2): 203-206.
[15]	LI Peng-fei, LIU Li-hong, MA Ping, DING Chun-lei, TONG Wei-hang. Comparison on two methods of HPLC-MS/MS and MEIA in monitoring the tacrolimus concentrations for organ transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(1): 80-83.